VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells

Abstract excerpt

BACKGROUND: Glioblastomas treated with temozolomide frequently develop resistance to pharmacological treatments. Therefore, there is a need to find alternative drug targets to reduce treatment resistance based on tumor dependencies. A possibility is to target simultaneously two proteins from different DNA-damage repair pathways to facilitate tumor cell death. Therefore, we tested whether targeting the human...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Microtubule and mitosis dynamics
• Share to Nuclear Structure and Function
• Share to PARP inhibition in cancer therapy